Cargando…

p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma

p53 abnormalities are regarded as an independent prognostic marker in multiple myeloma. Patients harbouring this genetic anomaly are commonly resistant to standard therapy. Thus, various p53 reactivating agents have been developed in order to restore its tumour suppressive abilities. Small molecular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teoh, P. J., Chng, W. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083709/ https://www.ncbi.nlm.nih.gov/pubmed/25028664 http://dx.doi.org/10.1155/2014/717919

Ejemplares similares

P833: MARCH5 AS A POTENTIAL THERAPEUTIC TARGET IN MULTIPLE MYELOMA
por: Bashiri, Hamed, et al.
Publicado: (2023)

STAT3: A Promising Therapeutic Target in Multiple Myeloma
por: Chong, Phyllis S. Y., et al.
Publicado: (2019)

MMSET: Role and Therapeutic Opportunities in Multiple Myeloma
por: Xie, Zhigang, et al.
Publicado: (2014)

Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
por: Cardona-Benavides, Ignacio J., et al.
Publicado: (2021)

CAR T-cell therapy in multiple myeloma: more room for improvement
por: Teoh, Phaik Ju, et al.
Publicado: (2021)

Targeting p53 by small molecule p53 activators in multiple myeloma
por: Saha, Manujendra N, et al.
Publicado: (2012)

The therapeutic potential of cell cycle targeting in multiple myeloma
por: Maes, Anke, et al.
Publicado: (2017)

Potential Clinical Application of Genomics in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2018)

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma
por: Flynt, Erin, et al.
Publicado: (2020)

Targeting NF-κB Signaling for Multiple Myeloma
por: Wong, Ada Hang-Heng, et al.
Publicado: (2020)

Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma
por: Ye, Fang, et al.
Publicado: (2021)

The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma
por: Zhu, Bingying, et al.
Publicado: (2018)

Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma
por: Zeissig, Mara N., et al.
Publicado: (2020)

Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2022)

Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma
por: Herrero, Ana B., et al.
Publicado: (2016)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

Genetic Abnormalities in Extramedullary Multiple Myeloma
por: McAvera, Roisin, et al.
Publicado: (2023)

Possible Therapeutic Potential of Disulfiram for Multiple Myeloma
por: Weiser Drozdkova, Denisa, et al.
Publicado: (2021)

Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma
por: Thomas, Alexandra L., et al.
Publicado: (2015)

Autophagy: A Potential Therapeutic Target to Tackle Drug Resistance in Multiple Myeloma
por: Bashiri, Hamed, et al.
Publicado: (2023)

Metabolic Vulnerabilities in Multiple Myeloma
por: Lim, Julia S. L., et al.
Publicado: (2022)

PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation
por: Teoh, Phaik Ju, et al.
Publicado: (2016)

Nucleotide excision repair is a potential therapeutic target in multiple myeloma
por: Szalat, R, et al.
Publicado: (2018)

Proteasome inhibition and its therapeutic potential in multiple myeloma
por: Chari, Ajai, et al.
Publicado: (2010)

Transcription/Replication Conflicts in Tumorigenesis and Their Potential Role as Novel Therapeutic Targets in Multiple Myeloma
por: Dutrieux, Laure, et al.
Publicado: (2021)

Implications of Heterogeneity in Multiple Myeloma
por: de Mel, Sanjay, et al.
Publicado: (2014)

Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
por: Jovanović, Katarina K., et al.
Publicado: (2019)

IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification
por: Teoh, Phaik Ju, et al.
Publicado: (2020)

RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53(abnormal) myeloma cells independently of the p53 pathway
por: Surget, Sylvanie, et al.
Publicado: (2014)

MicroRNA: Important Player in the Pathobiology of Multiple Myeloma
por: Bi, Chonglei, et al.
Publicado: (2014)

The Double Role of p53 in Cancer and Autoimmunity and Its Potential as Therapeutic Target
por: Fierabracci, Alessandra, et al.
Publicado: (2016)

Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis
por: Abdi, Jahangir, et al.
Publicado: (2017)

Anticancer Therapeutic Strategies Targeting p53 Aggregation
por: Ferretti, Giulia D. S., et al.
Publicado: (2022)

Targeting IL-17A in Multiple Myeloma: A Potential Novel Therapeutic Approach in Myeloma
por: Prabhala, Rao H., et al.
Publicado: (2015)

Circular RNA as a Novel Biomarker for Diagnosis and Prognosis and Potential Therapeutic Targets in Multiple Myeloma
por: Allegra, Alessandro, et al.
Publicado: (2022)

Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2021)

The Potential of JAG Ligands as Therapeutic Targets and Predictive Biomarkers in Multiple Myeloma
por: Platonova, Natalia, et al.
Publicado: (2023)

Chromosome 1q21 abnormalities in multiple myeloma
por: Schmidt, Timothy M., et al.
Publicado: (2021)

Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC
por: Zhang, Yaqun, et al.
Publicado: (2019)

p53 Isoforms as Cancer Biomarkers and Therapeutic Targets
por: Zhao, Liuqun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ojb518n0gggc4kjsdqgtg06r3t